Related Experiment Video
Updated: Nov 1, 2025

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
Managing diabetes in diabetic patients with COVID: where do we start from?
Angelo Avogaro1, Benedetta Bonora2, Gian Paolo Fadini2
1Department of Medicine, Unit of Metabolic Disease, University of Padova, Via Giustiniani 2, 35128, Padova, Italy. angelo.avogaro@unipd.it.
Aims:
COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality.
Methods:
We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2.
Results:
Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral.
Conclusions:
The totality of articles reports retrospective data strongly affected by "channeling bias" so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.
Insights
Metformin may reduce mortality risk in patients with diabetes during the COVID-19 pandemic. However, insulin might increase this risk, though data is limited by channeling bias in retrospective studies.
Area of Science:
- Endocrinology
- Infectious Diseases
- Pharmacology
Background:
- The COVID-19 pandemic has overwhelmed global healthcare systems.
- Understanding the impact of antidiabetic treatments on COVID-19 outcomes is crucial.
Purpose of the Study:
- To review evidence on antidiabetic treatments and their association with COVID-19 mortality.
- To identify specific antidiabetic drugs that may mitigate or exacerbate mortality risk.
Main Methods:
- Systematic literature search of PubMed and EMBASE (March 2020 - March 2021).
- Inclusion of studies with mortality as an outcome; exclusion of non-original research.
- Meta-analysis for metformin and insulin using Cochrane RevMan 5.2.
Main Results:
- Metformin was the only antidiabetic drug associated with a reduced risk of COVID-19-related mortality.
- Insulin use appeared linked to an increased risk of mortality.
- Other antidiabetic drug classes showed neutral associations with mortality.
Conclusions:
- Existing evidence is largely retrospective and subject to significant channeling bias.
- Patient phenotype influences the prescription of specific antidiabetic drugs, potentially confounding mortality results.
- Further research is needed to clarify the true impact of antidiabetic treatments on COVID-19 mortality.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

